Table of Content




1 INTRODUCTION 17
1.1 OBJECTIVES OF THE STUDY 17
1.2 MARKET DEFINITION 17
1.3 MARKET SCOPE 18
1.3.1 MARKETS COVERED 18
1.3.2 YEARS CONSIDERED FOR THE STUDY 18
1.4 CURRENCY 19
1.5 LIMITATIONS 19
1.6 STAKEHOLDERS 19

2 RESEARCH METHODOLOGY 20
2.1 RESEARCH DATA 20
2.1.1 SECONDARY SOURCES 21
2.1.1.1 Key data from secondary sources 22
2.1.2 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Key industry insights 23
2.2 MARKET SIZE ESTIMATIONS 24
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 26
2.4 ASSUMPTIONS FOR THE STUDY 27

3 EXECUTIVE SUMMARY 28

4 PREMIUM INSIGHTS 31
4.1 WOMEN’S HEALTHCARE MARKET OVERVIEW 31
4.2 WOMEN’S HEALTHCARE MARKET, BY DRUG (2019–2024) 32
4.3 WOMEN’S HEALTHCARE MARKET, BY APPLICATION (2019 VS. 2024) 33
4.4 WOMEN’S HEALTHCARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 34

5 MARKET OVERVIEW 35
5.1 INTRODUCTION 35
5.2 MARKET DYNAMICS 35
5.2.1 MARKET DRIVERS 36
5.2.1.1 Growing incidence of chronic health conditions among women 36
5.2.1.2 Demand for contraceptives to prevent unintended pregnancies 36
5.2.1.3 Government initiatives to curb population growth 36
5.2.1.4 Growing focus on product R&D 37
?
5.2.2 MARKET OPPORTUNITIES 38
5.2.2.1 Emerging markets 38
5.2.3 MARKET CHALLENGES 38
5.2.3.1 Reluctance to use contraceptives 38

6 WOMEN’S HEALTHCARE MARKET, BY DRUG 39
6.1 INTRODUCTION 40
6.2 PROLIA 40
6.2.1 PROLIA ACCOUNTS FOR THE LARGEST SHARE OF THE WOMEN’S HEALTHCARE MARKET 40
6.3 XGEVA 43
6.3.1 XGEVA IS PRIMARILY MARKETED IN THE US AND EUROPEAN COUNTRIES 43
6.4 FORTEO 45
6.4.1 ELI LILLY IS EXPECTED TO EXPERIENCE A REVENUE DECLINE IN THE COMING YEARS DUE TO THE PATENT EXPIRY OF FORTEO 45
6.5 MIRENA 47
6.5.1 MIRENA IS WIDELY ACCEPTED AMONGST END USERS OWING TO THE MINIMAL SIDE-EFFECTS ASSOCIATED WITH IT 47
6.6 NUVARING 49
6.6.1 NUVARING IS ONE OF THE TOP-SELLING DRUGS FROM MERCK IN THE WOMEN’S HEALTH CATEGORY 49
6.7 PREMARIN 51
6.7.1 PREMARIN IS USED FOR THE TREATMENT OF OSTEOPOROSIS IN WOMEN 51
6.8 ORTHO TRI-CY LO (28) 53
6.8.1 GROWING NUMBER OF ANDA TO MARKET GENERIC VERSIONS OF ORTHO TRI-CY LO (28) TO HAMPER ITS SALES IN THE COMING YEARS 53
6.9 EVISTA 55
6.9.1 INTENSE GENERIC COMPETITION HAS LED TO A YEAR-ON-YEAR DECLINE IN EVISTA’S SALES 55
6.10 RECLAST/ACLASTA 57
6.10.1 ACLASTA HAS MORE BENEFITS AS COMPARED TO OTHER DRUGS 57
6.11 ZOMETA 59
6.11.1 EARLY PATENT EXPIRY OF ZOMETA IN THE US AND EUROPE HAS AFFECTED ITS SALES 59
6.12 MINASTRIN 24 FE 61
6.12.1 AVAILABILITY OF LOW-PRICED GENERIC VERSIONS OF MINASTRIN 24 FE IS ONE OF THE MAIN REASONS FOR THE LOWER SALES OF THIS DRUG 61
6.13 ACTONEL 62
6.13.1 INTENSE COMPETITION IN THE OSTEOPOROSIS MARKET HAS LED TO A SALES DECLINE IN ACTONEL IN THE LAST FEW YEARS 62
6.14 PIPELINE DRUGS 64
?

7 WOMEN’S HEALTHCARE MARKET, BY APPLICATION 65
7.1 INTRODUCTION 66
7.2 POSTMENOPAUSAL OSTEOPOROSIS 66
7.2.1 HIGH PREVALENCE OF OSTEOPOROSIS IN WOMEN HAS PROMPTED COMPANIES TO FOCUS ON THIS THERAPEUTIC AREA 66
7.3 CONTRACEPTIVES 68
7.3.1 BENEFITS OFFERED BY CONTRACEPTIVES DRIVING THEIR DEMAND AMONG END USERS 68
7.4 MENOPAUSE 70
7.4.1 DEMAND FOR NON-HORMONAL THERAPIES HAS INCREASED OVER THE LAST FEW YEARS 70
7.5 HORMONAL INFERTILITY 71
7.5.1 INCREASING AWARENESS ABOUT OVULATION HEALTH TO SUPPORT MARKET GROWTH 71
7.6 POLYCYSTIC OVARY SYNDROME 73
7.6.1 GROWING PREVALENCE OF PCOS IS RESPONSIBLE FOR MARKET GROWTH 73
7.7 ENDOMETRIOSIS 75
7.7.1 ORILISSA IS THE FIRST AND ONLY ORAL TREATMENT SPECIFICALLY AVAILABLE FOR WOMEN WITH ENDOMETRIOSIS PAIN 75
7.8 OTHER APPLICATIONS 77

8 WOMEN’S HEALTHCARE MARKET, BY REGION 79
8.1 INTRODUCTION 80
8.2 NORTH AMERICA 80
8.2.1 US 83
8.2.1.1 Strong economy and high contraception awareness are key factors driving market growth in the US 83
8.2.2 CANADA 85
8.2.2.1 Growing prevalence of PCOS and obesity to support market growth in Canada 85
8.3 EUROPE 86
8.3.1 GERMANY 89
8.3.1.1 Germany holds the largest share of the women’s healthcare market in Europe 89
8.3.2 UK 91
8.3.2.1 Government support and favorable training programs are major market drivers in the UK 91
8.3.3 FRANCE 92
8.3.3.1 High prevalence of lifestyle disorders among women in France to support market growth 92
8.3.4 ITALY 94
8.3.4.1 Relatively high awareness of contraceptives to drive market growth in Italy 94
8.3.5 SPAIN 95
8.3.5.1 Improved healthcare expenditure to support the market in Spain 95
8.3.6 REST OF EUROPE 97
8.4 ASIA PACIFIC 98
8.4.1 JAPAN 100
8.4.1.1 Japan dominates the APAC market for women’s healthcare 100
8.4.2 CHINA 102
8.4.2.1 Growing population and urbanization are factors responsible for the growth of the market in China 102
8.4.3 INDIA 103
8.4.3.1 Increasing government initiatives to curb population growth will drive market growth in India 103
8.4.4 REST OF APAC 105
8.5 LATIN AMERICA 106
8.5.1 INCREASING LIFESTYLE DISEASES AND AWARENESS AMONG WOMEN TO DRIVE MARKET GROWTH IN LATIN AMERICA 106
8.6 MIDDLE EAST & AFRICA 108
8.6.1 INCREASING GOVERNMENT INITIATIVES TO CURB POPULATION GROWTH WILL DRIVE MARKET GROWTH IN INDIA 108

9 COMPETITIVE LANDSCAPE 110
9.1 OVERVIEW 110
9.2 MARKET SHARE ANALYSIS 110
9.3 COMPETITIVE LEADERSHIP MAPPING 112
9.3.1 VISIONARY LEADERS 112
9.3.2 DYNAMIC DIFFERENTIATORS 112
9.3.3 INNOVATORS 112
9.3.4 EMERGING COMPANIES 112
?

10 COMPANY PROFILES 114
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
10.1 AMGEN 114
10.2 BAYER AG 116
10.3 ELI LILLY AND COMPANY 119
10.4 MERCK & CO. 121
10.5 PFIZER 123
10.6 ALLERGAN 125
10.7 JOHNSON & JOHNSON SERVICES INC. 128
10.8 NOVARTIS AG 130
10.9 MYLAN NV 131
10.10 LUPIN LIMITED 133
10.11 AGILE THERAPEUTICS 135
10.12 FERRING PHARMACEUTICALS 136
10.13 BLAIREX LABORATORIES, INC. 138
10.14 APOTHECUS PHARMACEUTICAL CORPORATION 139
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

11 APPENDIX 140
11.1 DISCUSSION GUIDE 140
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 143
11.3 AVAILABLE CUSTOMIZATIONS 145
11.4 RELATED REPORTS 145
11.5 AUTHOR DETAILS 146



List of Figures



FIGURE 1 RESEARCH DESIGN 20
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS 24
FIGURE 3 BOTTOM-UP APPROACH 25
FIGURE 4 TOP-DOWN APPROACH 25
FIGURE 5 DATA TRIANGULATION METHODOLOGY 26
FIGURE 6 WOMEN’S HEALTHCARE MARKET, BY DRUG, 2019 VS. 2024 (USD MILLION) 28
FIGURE 7 WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2019 VS. 2024 (USD MILLION) 29
FIGURE 8 GEOGRAPHICAL SNAPSHOT OF THE WOMEN’S HEALTHCARE MARKET 30
FIGURE 9 GROWING INCIDENCE OF CHRONIC HEALTH CONDITIONS AMONG WOMEN IS A MAJOR FACTOR DRIVING THE WOMEN’S HEALTHCARE MARKET 31
FIGURE 10 PROLIA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 32
FIGURE 11 POSTMENOPAUSAL OSTEOPOROSIS TO DOMINATE THE WOMEN’S HEALTHCARE APPLICATIONS MARKET DURING THE FORECAST PERIOD 33
FIGURE 12 NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR WOMEN’S HEALTHCARE PRODUCTS 34
FIGURE 13 WOMEN’S HEALTHCARE MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 35
FIGURE 14 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET SNAPSHOT 81
FIGURE 15 EUROPE: WOMEN’S HEALTHCARE MARKET SNAPSHOT 87
FIGURE 16 WOMEN’S HEALTHCARE MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018 110
FIGURE 17 COMPETITIVE LEADERSHIP MAPPING OF THE WOMEN’S HEALTHCARE
MARKET, 2018 113
FIGURE 18 AMGEN: COMPANY SNAPSHOT 114
FIGURE 19 BAYER AG: COMPANY SNAPSHOT 116
FIGURE 20 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 119
FIGURE 21 MERCK & CO.: COMPANY SNAPSHOT 121
FIGURE 22 PFIZER: COMPANY SNAPSHOT 123
FIGURE 23 ALLERGAN: COMPANY SNAPSHOT 125
FIGURE 24 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT 128
FIGURE 25 NOVARTIS AG: COMPANY SNAPSHOT 130
FIGURE 26 MYLAN NV: COMPANY SNAPSHOT 131
FIGURE 27 LUPIN LIMITED: COMPANY SNAPSHOT 133

 

List of Tables



TABLE 1 WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 40
TABLE 2 PROLIA: PRODUCT HIGHLIGHTS 41
TABLE 3 WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY REGION 2017–2024 (USD MILLION) 41
TABLE 4 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR PROLIA BY COUNTRY, 2017–2024 (USD MILLION) 41
TABLE 5 EUROPE: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY 2017–2024 (USD MILLION) 42
TABLE 6 APAC: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY 2017–2024 (USD MILLION) 42
TABLE 7 XGEVA: PRODUCT HIGHLIGHTS 43
TABLE 8 WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY REGION 2017–2024 (USD MILLION) 43
TABLE 9 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR XGEVA BY COUNTRY, 2017–2024 (USD MILLION) 44
TABLE 10 EUROPE: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY 2017–2024 (USD MILLION) 44
TABLE 11 APAC: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY 2017–2024 (USD MILLION) 44
TABLE 12 FORTEO: PRODUCT HIGHLIGHTS 45
TABLE 13 WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY REGION 2017–2024 (USD MILLION) 45
TABLE 14 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY, 2017–2024 (USD MILLION) 46
TABLE 15 EUROPE: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY 2017–2024 (USD MILLION) 46
TABLE 16 APAC: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY 2017–2024 (USD MILLION) 46
TABLE 17 MIRENA: PRODUCT HIGHLIGHTS 47
TABLE 18 WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY REGION 2017–2024 (USD MILLION) 47
TABLE 19 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MIRENA BY COUNTRY, 2017–2024 (USD MILLION) 48
TABLE 20 EUROPE: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY 2017–2024 (USD MILLION) 48
TABLE 21 APAC: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY 2017–2024 (USD MILLION) 48
TABLE 22 NUVARING: PRODUCT HIGHLIGHTS 49
TABLE 23 WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY REGION 2017–2024 (USD MILLION) 49
TABLE 24 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY, 2017–2024 (USD MILLION) 50
TABLE 25 EUROPE: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY 2017–2024 (USD MILLION) 50
TABLE 26 APAC: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY 2017–2024 (USD MILLION) 50
TABLE 27 PREMARIN: PRODUCT HIGHLIGHTS 51
TABLE 28 WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY REGION 2017–2024 (USD MILLION) 51
TABLE 29 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR PREMARIN BY COUNTRY, 2017–2024 (USD MILLION) 52
TABLE 30 EUROPE: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY 2017–2024 (USD MILLION) 52
TABLE 31 APAC: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY 2017–2024 (USD MILLION) 52
TABLE 32 ORTHO TRI-CY LO (28): PRODUCT HIGHLIGHTS 53
TABLE 33 WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY REGION 2017–2024 (USD MILLION) 53
TABLE 34 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28) BY COUNTRY, 2017–2024 (USD MILLION) 54
TABLE 35 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28) BY COUNTRY, 2017–2024 (USD MILLION) 54
TABLE 36 APAC: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28) BY COUNTRY, 2017–2024 (USD MILLION) 54
TABLE 37 EVISTA: PRODUCT HIGHLIGHTS 55
TABLE 38 WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY REGION 2017–2024 (USD MILLION) 55
TABLE 39 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY, 2017–2024 (USD MILLION) 56
TABLE 40 EUROPE: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY 2017–2024 (USD MILLION) 56
TABLE 41 APAC: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY 2017–2024 (USD MILLION) 56
TABLE 42 RECLAST/ACLASTA: PRODUCT HIGHLIGHTS 57
TABLE 43 WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY REGION 2017–2024 (USD MILLION) 57
TABLE 44 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA BY COUNTRY, 2017–2024 (USD MILLION) 58
TABLE 45 EUROPE: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA BY COUNTRY, 2017–2024 (USD MILLION) 58
TABLE 46 APAC: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA BY COUNTRY, 2017–2024 (USD MILLION) 58
TABLE 47 ZOMETA: PRODUCT HIGHLIGHTS 59
TABLE 48 WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY REGION 2017–2024 (USD MILLION) 59
TABLE 49 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY, 2017–2024 (USD MILLION) 60
TABLE 50 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY 2017–2024 (USD MILLION) 60
TABLE 51 APAC: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY 2017–2024 (USD MILLION) 60
TABLE 52 MINASTRIN 24 FE: PRODUCT HIGHLIGHTS 61
TABLE 53 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MINASTRIN 24 FE BY COUNTRY, 2017–2024 (USD MILLION) 61
TABLE 54 ACTONEL: PRODUCT HIGHLIGHTS 62
TABLE 55 WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY REGION 2017–2024 (USD MILLION) 62
TABLE 56 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY, 2017–2024 (USD MILLION) 63
TABLE 57 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY 2017–2024 (USD MILLION) 63
TABLE 58 APAC: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY 2017–2024 (USD MILLION) 63
TABLE 59 INDICATIVE LIST OF DRUGS IN PHASE III 64
TABLE 60 WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 66
TABLE 61 WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS BY REGION, 2017–2024 (USD MILLION) 67
TABLE 62 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION) 67
TABLE 63 EUROPE: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION) 67
TABLE 64 APAC: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION) 68
TABLE 65 WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY REGION 2017–2024 (USD MILLION) 68
TABLE 66 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES BY COUNTRY, 2017–2024 (USD MILLION) 69
TABLE 67 EUROPE: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION) 69
TABLE 68 APAC: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION) 69
TABLE 69 WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY REGION 2017–2024 (USD MILLION) 70
TABLE 70 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE BY COUNTRY, 2017–2024 (USD MILLION) 70
TABLE 71 EUROPE: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY, 2017–2024 (USD MILLION) 71
TABLE 72 APAC: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY 2017–2024 (USD MILLION) 71
TABLE 73 WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY REGION, 2017–2024 (USD MILLION) 72
TABLE 74 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY COUNTRY, 2017–2024 (USD MILLION) 72
TABLE 75 EUROPE: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY BY COUNTRY, 2017–2024 (USD MILLION) 73
TABLE 76 APAC: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY BY COUNTRY, 2017–2024 (USD MILLION) 73
TABLE 77 WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME BY REGION, 2017–2024 (USD MILLION) 74
TABLE 78 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD MILLION) 74
TABLE 79 EUROPE: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD THOUSAND) 74
TABLE 80 APAC: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME BY COUNTRY, 2017–2024 (USD MILLION) 75
TABLE 81 WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY REGION 2017–2024 (USD MILLION) 75
TABLE 82 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS BY COUNTRY, 2017–2024 (USD MILLION) 76
TABLE 83 EUROPE: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD THOUSAND) 76
TABLE 84 APAC: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD MILLION) 76
TABLE 85 WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY REGION 2017–2024 (USD MILLION) 77
TABLE 86 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2017–2024 (USD MILLION) 77
TABLE 87 EUROPE: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS BY COUNTRY, 2017–2024 (USD MILLION) 78
TABLE 88 APAC: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION) 78
TABLE 89 WOMEN’S HEALTHCARE MARKET, BY REGION, 2017–2024 (USD MILLION) 80
TABLE 90 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY COUNTRY 2017–2024 (USD MILLION) 81
TABLE 91 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY DRUG 2017–2024 (USD MILLION) 82
TABLE 92 NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 82
TABLE 93 US: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 84
TABLE 94 US: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 84
TABLE 95 CANADA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 85
TABLE 96 CANADA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 86
TABLE 97 EUROPE: WOMEN’S HEALTHCARE MARKET, BY COUNTRY 2017–2024 (USD MILLION) 88
TABLE 98 EUROPE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 88
TABLE 99 EUROPE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 89
TABLE 100 GERMANY: WOMEN’S HEALTHCARE MARKET, BY DRUG 2017–2024 (USD MILLION) 90
TABLE 101 GERMANY: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 90
TABLE 102 UK: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 91
TABLE 103 UK: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 92
TABLE 104 FRANCE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 93
TABLE 105 FRANCE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 93
TABLE 106 ITALY: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 94
TABLE 107 ITALY: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 95
TABLE 108 SPAIN: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 96
TABLE 109 SPAIN: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD THOUSAND) 96
TABLE 110 ROE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 97
TABLE 111 ROE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 97
TABLE 112 ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY COUNTRY 2017–2024 (USD MILLION) 98
TABLE 113 ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY DRUG 2017–2024 (USD MILLION) 99
TABLE 114 ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 99
TABLE 115 JAPAN: INDICATIVE LIST OF CONFERENCES 100
TABLE 116 JAPAN: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 101
TABLE 117 JAPAN: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 101
TABLE 118 CHINA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 102
TABLE 119 CHINA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 103
TABLE 120 INDIA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 104
TABLE 121 INDIA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 104
TABLE 122 ROAPAC: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION) 105
TABLE 123 ROAPAC: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 106
TABLE 124 LATIN AMERICA: WOMEN’S HEALTHCARE MARKET, BY DRUG 2017–2024 (USD MILLION) 107
TABLE 125 LATIN AMERICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION 2017–2024 (USD MILLION) 107
TABLE 126 MIDDLE EAST & AFRICA: WOMEN’S HEALTHCARE MARKET, BY DRUG 2017–2024 (USD MILLION) 108
TABLE 127 MIDDLE EAST & AFRICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION) 109